SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXV_E_MTXE2000_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1guq	GALACTOSE-1-PHOSPHAT E URIDYLYLTRANSFERASE (Escherichia coli)	PF01087 (GalP_UDP_transf) PF02744 (GalP_UDP_tr_C)	5	ARG A 204 ARG A 336 VAL A 213 ALA A 328 TYR A 225	None	1.29A	3qxvE-1guqA: undetectable	3qxvE-1guqA: 15.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 77 VAL A 84 ALA A 103 TYR A 118	None None None None CGN A 1 ( 4.0A)	0.85A	3qxvE-1i3uA: 18.3	3qxvE-1i3uA: 59.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1j33	COBT (Thermus thermophilus)	PF02277 (DBI_PRT)	5	ALA A 204 ARG A 200 SER A 64 VAL A 225 ALA A 172	None	1.20A	3qxvE-1j33A: undetectable	3qxvE-1j33A: 17.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1jn0	GLYCERALDEHYDE-3-PHO SPHATE DEHYDROGENASE A (Spinacia oleracea)	no annotation	5	ALA O 257 SER O 294 SER O 295 VAL O 160 ALA O 263	None	1.33A	3qxvE-1jn0O: undetectable	3qxvE-1jn0O: 15.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 ALA B 94 TYR B 102	None	1.07A	3qxvE-1kxtB: 16.3	3qxvE-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pz5	HEAVY CHAIN OF FAB (SYA/J6) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 VAL B 78 TYR B 102	None	0.94A	3qxvE-1pz5B: 16.4	3qxvE-1pz5B: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1qd0	VHH-R2 ANTI-RR6 ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 37 ARG A 75 VAL A 82 ALA A 101 TYR A 117	None	1.02A	3qxvE-1qd0A: 16.5	3qxvE-1qd0A: 71.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1shm	ANTIBODY RIG (Lama glama)	PF07686 (V-set)	5	CYH A 22 ALA A 24 SER A 30 VAL A 78 ALA A 94	None	0.97A	3qxvE-1shmA: 18.2	3qxvE-1shmA: 65.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1shm	ANTIBODY RIG (Lama glama)	PF07686 (V-set)	5	CYH A 22 SER A 30 MET A 34 VAL A 78 ALA A 94	None	1.01A	3qxvE-1shmA: 18.2	3qxvE-1shmA: 65.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t3q	QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT (Pseudomonas putida)	PF01315 (Ald_Xan_dh_C) PF02738 (Ald_Xan_dh_C2)	5	ALA B 314 ARG B 416 SER B 354 ARG B 188 ALA B 177	None	1.22A	3qxvE-1t3qB: undetectable	3qxvE-1t3qB: 10.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t3q	QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT (Pseudomonas putida)	PF01315 (Ald_Xan_dh_C) PF02738 (Ald_Xan_dh_C2)	5	ALA B 314 ARG B 416 SER B 354 ARG B 188 VAL B 186	None	0.83A	3qxvE-1t3qB: undetectable	3qxvE-1t3qB: 10.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1up2	CELA1 PROTEIN (Mycobacterium tuberculosis)	PF01341 (Glyco_hydro_6)	5	ALA A 268 SER A 298 SER A 292 VAL A 226 TYR A 242	None	1.31A	3qxvE-1up2A: undetectable	3qxvE-1up2A: 19.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1urj	MAJOR DNA-BINDING PROTEIN (Human alphaherpesvirus 1)	PF00747 (Viral_DNA_bp)	5	ALA A 243 SER A 92 TYR A 95 VAL A 46 ALA A 39	None	1.30A	3qxvE-1urjA: undetectable	3qxvE-1urjA: 8.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ck0	HEAVY CHAIN) PROTEIN (IMMUNOGLOBULIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	CYH H 22 ALA H 24 MET H 34 ARG H 71 TYR H 106	None	1.15A	3qxvE-2ck0H: 16.7	3qxvE-2ck0H: 36.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgv	TAGATOSE-6-PHOSPHATE KINASE (Staphylococcus aureus)	PF00294 (PfkB)	5	ALA A 230 ARG A 238 SER A 222 VAL A 181 ALA A 277	None	1.08A	3qxvE-2jgvA: undetectable	3qxvE-2jgvA: 16.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2uxy	ALIPHATIC AMIDASE (Pseudomonas aeruginosa)	PF00795 (CN_hydrolase)	5	ALA A 256 ARG A 2 SER A 8 TYR A 255 VAL A 17	None	1.31A	3qxvE-2uxyA: undetectable	3qxvE-2uxyA: 16.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	5	MET A 34 ARG A 73 VAL A 80 ALA A 99 TYR A 115	None	1.05A	3qxvE-2x6mA: 17.4	3qxvE-2x6mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	5	SER A 29 MET A 34 VAL A 78 ALA A 94 TYR A 102	SO4 A1114 (-2.7A) None None None None	0.77A	3qxvE-2xa3A: 17.2	3qxvE-2xa3A: 69.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3cp0	MEMBRANE PROTEIN IMPLICATED IN REGULATION OF MEMBRANE PROTEASE ACTIVITY (Corynebacterium glutamicum)	PF01957 (NfeD)	5	ALA A 26 SER A 44 TRP A 46 VAL A 32 ALA A 73	None	1.03A	3qxvE-3cp0A: undetectable	3qxvE-3cp0A: 23.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94 TYR B 102	None	0.68A	3qxvE-3g9aB: 16.4	3qxvE-3g9aB: 64.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gkf	ALDOLASE LSRF (Escherichia coli)	no annotation	5	CYH O 239 ALA O 235 SER O 259 VAL O 250 ALA O 268	None	1.15A	3qxvE-3gkfO: undetectable	3qxvE-3gkfO: 14.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 111	None	0.51A	3qxvE-3k7uA: 18.7	3qxvE-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ln9	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10 (Camelidae)	PF07686 (V-set)	5	ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None None None None GOL A 137 (-4.8A)	0.84A	3qxvE-3ln9A: 16.0	3qxvE-3ln9A: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	5	ALA A 26 SER A 30 VAL A 81 ALA A 100 TYR A 120	None	0.98A	3qxvE-3qxuA: 20.4	3qxvE-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	ALA A 26 SER A 31 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	0.88A	3qxvE-3qxuA: 20.4	3qxvE-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	SER A 31 TRP A 34 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	1.44A	3qxvE-3qxuA: 20.4	3qxvE-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	CYH A 24 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.69A	3qxvE-3qycA: 16.4	3qxvE-3qycA: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sge	HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	ALA H 24 SER H 28 MET H 34 ARG H 74 TYR H 104	None	1.02A	3qxvE-3sgeH: 16.5	3qxvE-3sgeH: 37.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	5	ALA A 26 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.66A	3qxvE-3stbA: 18.4	3qxvE-3stbA: 70.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3um1	BRO1 DOMAIN-CONTAINING PROTEIN BROX (Homo sapiens)	PF03097 (BRO1)	5	CYH A 187 ARG A 145 VAL A 184 ALA A 119 TYR A 122	None	1.15A	3qxvE-3um1A: undetectable	3qxvE-3um1A: 15.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aq1	NBKB6 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	1.03A	3qxvE-4aq1B: 18.2	3qxvE-4aq1B: 74.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bk1	PROBABLE SALICYLATE MONOOXYGENASE (Rhodococcus jostii)	PF01494 (FAD_binding_3)	5	ALA A 252 SER A 213 TYR A 253 ALA A 184 TYR A 183	None	1.22A	3qxvE-4bk1A: undetectable	3qxvE-4bk1A: 16.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bm1	MANGANESE PEROXIDASE 4 (Pleurotus ostreatus)	PF00141 (peroxidase) PF11895 (Peroxidase_ext)	5	ALA A 115 ARG A 126 SER A 286 ARG A 133 ALA A 270	None	1.20A	3qxvE-4bm1A: undetectable	3qxvE-4bm1A: 16.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4czp	EXTRALONG MANGANESE PEROXIDASE (Gelatoporia subvermispora)	PF00141 (peroxidase) PF11895 (Peroxidase_ext)	5	ALA A 111 ARG A 122 SER A 294 ARG A 129 ALA A 278	None	1.17A	3qxvE-4czpA: undetectable	3qxvE-4czpA: 16.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 116	None	0.76A	3qxvE-4dkaA: 18.4	3qxvE-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 97 TYR B 106	None	0.70A	3qxvE-4eigB: 16.5	3qxvE-4eigB: 66.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ej1	NB113 CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	ALA C 97 SER C 101 ARG C 72 VAL C 79 ALA C 50	None	1.16A	3qxvE-4ej1C: 17.6	3qxvE-4ej1C: 74.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	5	MET D 34 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.51A	3qxvE-4fhbD: 18.3	3qxvE-4fhbD: 71.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET B 36 ARG B 74 VAL B 81 ALA B 100 TYR B 115	None None None None PCA B 2 ( 3.9A)	0.37A	3qxvE-4gftB: 18.6	3qxvE-4gftB: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	6	ALA E 24 MET E 34 ARG E 72 VAL E 79 ALA E 98 TYR E 112	None	0.68A	3qxvE-4hemE: 19.7	3qxvE-4hemE: 73.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4i4n	INTRACELLULAR PROTEASE/AMIDASE (Vibrio cholerae)	no annotation	5	ALA A 142 SER A 93 TYR A 149 VAL A 173 ALA A 97	None	1.22A	3qxvE-4i4nA: undetectable	3qxvE-4i4nA: 17.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4kf7	NUP188 (Thermothelomyces thermophila)	PF10487 (Nup188)	5	ALA A1075 ARG A1072 SER A1070 VAL A1029 ALA A1006	None	1.24A	3qxvE-4kf7A: undetectable	3qxvE-4kf7A: 8.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.76A	3qxvE-4krmB: 19.7	3qxvE-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krn	NANOBODY/VHH DOMAIN EGA1 (Lama glama)	PF07686 (V-set)	5	ARG A 27 MET A 34 VAL A 79 ALA A 98 TYR A 119	None	1.29A	3qxvE-4krnA: 17.2	3qxvE-4krnA: 70.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lf0	ALIPHATIC AMIDASE (Bacillus sp. (in: Bacteria))	PF00795 (CN_hydrolase)	5	ALA A 256 ARG A 2 SER A 8 TYR A 255 VAL A 17	None	1.32A	3qxvE-4lf0A: undetectable	3qxvE-4lf0A: 15.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	CYH B 22 ALA B 24 SER B 28 MET B 34 ARG B 72 VAL B 79	None	0.94A	3qxvE-4lhqB: 18.3	3qxvE-4lhqB: 63.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4m3k	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-H7S (Lama glama)	PF07686 (V-set)	5	SER B 29 MET B 34 ARG B 71 VAL B 78 ALA B 97	None	1.24A	3qxvE-4m3kB: 15.1	3qxvE-4m3kB: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	6	ALA C 31 MET C 41 ARG C 79 VAL C 86 ALA C 105 TYR C 119	None	0.98A	3qxvE-4nc1C: 18.3	3qxvE-4nc1C: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.81A	3qxvE-4nc2B: 19.2	3qxvE-4nc2B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	5	MET G 34 ARG G 71 VAL G 78 ALA G 97 TYR G 111	None	0.57A	3qxvE-4p2cG: 16.0	3qxvE-4p2cG: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	5	SER G 27 MET G 34 VAL G 78 ALA G 97 TYR G 111	None	1.27A	3qxvE-4p2cG: 16.0	3qxvE-4p2cG: 70.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pdy	AMINOGLYCOSIDE PHOSPHOTRANSFERASE (Alicyclobacillus acidocaldarius)	PF01636 (APH)	5	ALA A 86 SER A 112 TRP A 110 VAL A 89 ALA A 56	None None HIS A 401 (-3.7A) None HIS A 401 (-3.5A)	1.22A	3qxvE-4pdyA: undetectable	3qxvE-4pdyA: 17.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None	0.83A	3qxvE-4qlrA: 18.6	3qxvE-4qlrA: 69.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	6	ALA A 25 MET A 35 ARG A 73 VAL A 80 ALA A 99 TYR A 113	None	0.62A	3qxvE-4qo1A: 18.1	3qxvE-4qo1A: 62.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qpk	PHOSPHOTRANSFERASE (Brucella abortus)	PF10090 (HPTransfase)	5	ALA A 65 ARG A 19 SER A 26 ALA A 60 TYR A 91	GOL A 301 (-3.6A) GOL A 302 (-3.0A) None None GOL A 301 (-4.9A)	1.30A	3qxvE-4qpkA: undetectable	3qxvE-4qpkA: 20.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	6	CYH a 23 ALA a 25 ARG a 73 VAL a 80 ALA a 99 TYR a 117	None	0.82A	3qxvE-4tvsa: 18.7	3qxvE-4tvsa: 72.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	0.99A	3qxvE-4w6yB: 17.6	3qxvE-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 118	None	1.31A	3qxvE-4w6yB: 17.6	3qxvE-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	5	ALA D 824 MET D 834 ARG D 872 ALA D 898 TYR D 910	None	0.66A	3qxvE-4weuD: 18.5	3qxvE-4weuD: 72.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wj1	ANTIGEN MTB48, MYCOBACTERIAL PROTEIN (Mycolicibacterium smegmatis)	no annotation	5	ALA A 220 SER A 41 TYR A 266 VAL A 225 ALA A 150	None	1.16A	3qxvE-4wj1A: undetectable	3qxvE-4wj1A: 17.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	5	ALA C 24 MET C 34 VAL C 78 ALA C 97 TYR C 107	None	0.87A	3qxvE-4xt1C: 16.2	3qxvE-4xt1C: 68.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	5	ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.78A	3qxvE-5a2kH: 16.4	3qxvE-5a2kH: 29.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5czr	CADHERIN-RELATED FAMILY MEMBER 2 (Homo sapiens)	PF00028 (Cadherin)	5	ALA A 62 MET A 42 VAL A 52 ALA A 47 TYR A 48	None	1.28A	3qxvE-5czrA: undetectable	3qxvE-5czrA: 18.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	5	ALA A 24 MET A 34 ARG A 71 VAL A 78 TYR A 102	None	0.86A	3qxvE-5fwoA: 18.2	3qxvE-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.58A	3qxvE-5fwoA: 18.2	3qxvE-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gru	DIABODY PROTEIN (Mus musculus)	PF07686 (V-set)	5	ALA L 153 SER L 214 SER L 215 MET L 125 ALA L 146	ALA L 153 ( 0.0A) SER L 214 ( 0.0A) SER L 215 ( 0.0A) MET L 125 ( 0.0A) ALA L 146 ( 0.0A)	1.25A	3qxvE-5gruL: 16.2	3qxvE-5gruL: 44.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	CYH B 22 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	0.81A	3qxvE-5gxbB: 17.4	3qxvE-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 MET B 34 VAL B 77 ALA B 96 TYR B 108	None	1.00A	3qxvE-5hvfB: 15.1	3qxvE-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	5	ALA B 23 MET B 33 ARG B 71 ALA B 97 TYR B 113	None	0.82A	3qxvE-5imlB: 19.9	3qxvE-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	5	MET B 33 ARG B 71 VAL B 78 ALA B 97 TYR B 113	None	0.43A	3qxvE-5imlB: 19.9	3qxvE-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	6	ALA C 25 MET C 35 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.89A	3qxvE-5j1sC: 15.9	3qxvE-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	5	CYH C 23 ALA C 25 VAL C 79 ALA C 98 TYR C 112	None	0.68A	3qxvE-5j1sC: 15.9	3qxvE-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	5	CYH C 23 SER C 31 VAL C 79 ALA C 98 TYR C 112	None	1.27A	3qxvE-5j1sC: 15.9	3qxvE-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	6	CYH B 22 ALA B 24 ARG B 76 VAL B 83 ALA B 102 TYR B 117	None	0.68A	3qxvE-5j56B: 17.5	3qxvE-5j56B: 67.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jds	NANOBODY (Camelidae)	PF07686 (V-set)	5	SER B 29 MET B 34 VAL B 79 ALA B 98 TYR B 117	None	1.08A	3qxvE-5jdsB: 16.7	3qxvE-5jdsB: 67.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	5	MET D 34 ARG D 71 VAL D 78 ALA D 97 TYR D 108	None	0.94A	3qxvE-5jqhD: 16.1	3qxvE-5jqhD: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kel	C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN (Homo sapiens)	PF07686 (V-set)	5	ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.85A	3qxvE-5kelH: 14.8	3qxvE-5kelH: 51.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 ARG B 72 VAL B 79 ALA B 98 TYR B 122	None	0.51A	3qxvE-5lhqB: 18.1	3qxvE-5lhqB: 64.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.95A	3qxvE-5lmjA: 16.7	3qxvE-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	5	ALA C 27 MET C 37 ARG C 75 ALA C 101 TYR C 117	None None None None ACT C 202 (-4.4A)	0.58A	3qxvE-5lwfC: 18.5	3qxvE-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	5	MET C 37 ARG C 75 VAL C 82 ALA C 101 TYR C 117	None None None None ACT C 202 (-4.4A)	0.54A	3qxvE-5lwfC: 18.5	3qxvE-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	5	MET L 34 ARG L 72 VAL L 79 ALA L 98 TYR L 114	None	0.55A	3qxvE-5o8fL: 18.1	3qxvE-5o8fL: 68.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tws	HUMAN DNA POLYMERASE MU (Homo sapiens)	PF10391 (DNA_pol_lambd_f) PF14716 (HHH_8) PF14791 (DNA_pol_B_thumb) PF14792 (DNA_pol_B_palm)	5	ALA A 159 SER A 209 SER A 210 VAL A 228 ALA A 164	None	1.31A	3qxvE-5twsA: undetectable	3qxvE-5twsA: 15.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u3j	DH511.1 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	CYH H 22 ALA H 24 MET H 34 ARG H 71 ALA H 94	None	0.94A	3qxvE-5u3jH: 16.0	3qxvE-5u3jH: 54.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	MET p 34 ARG p 72 VAL p 79 ALA p 98 TYR p 114	None	0.70A	3qxvE-5uk4p: 17.7	3qxvE-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	ALA d 24 ARG d 72 VAL d 79 ALA d 98 TYR d 113	None	0.75A	3qxvE-5ukbd: 19.3	3qxvE-5ukbd: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vaq	NB914 (Lama glama)	no annotation	5	ALA B 24 SER B 30 ARG B 72 VAL B 79 ALA B 98	None	1.05A	3qxvE-5vaqB: 19.3	3qxvE-5vaqB: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	5	MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.61A	3qxvE-5vxjB: 15.7	3qxvE-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	6	CYH B 22 ALA B 24 MET B 34 ARG B 73 ALA B 99 TYR B 106	None	0.80A	3qxvE-5vxlB: 16.6	3qxvE-5vxlB: 66.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	6	CYH B 22 MET B 34 ARG B 73 VAL B 80 ALA B 99 TYR B 106	None	0.66A	3qxvE-5vxlB: 16.6	3qxvE-5vxlB: 66.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wa3	PYRIDINE SYNTHASE TBTD (Thermobispora bispora)	no annotation	5	ALA A 343 SER A 229 TYR A 347 VAL A 183 ALA A 173	None	1.20A	3qxvE-5wa3A: undetectable	3qxvE-5wa3A: 19.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	5	ALA A1024 MET A1034 VAL A1078 ALA A1097 TYR A1107	None	0.97A	3qxvE-5wb1A: 15.0	3qxvE-5wb1A: 15.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wb2	NANOBODY B1 (synthetic construct)	no annotation	5	ALA D 24 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.97A	3qxvE-5wb2D: 15.8	3qxvE-5wb2D: 68.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	5	ALA A 43 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.79A	3qxvE-5x0tA: 16.4	3qxvE-5x0tA: 31.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3r	PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1 (Mus musculus)	no annotation	5	ALA A1174 ARG A1176 SER A1250 VAL A1742 TYR A1184	None	1.30A	3qxvE-6b3rA: undetectable	3qxvE-6b3rA: 21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	5	ALA A 24 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.78A	3qxvE-6dbeA: 17.1	3qxvE-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 107	None	1.18A	3qxvE-6dbeA: 17.1	3qxvE-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	MET C 34 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.59A	3qxvE-6ehgC: 18.8	3qxvE-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ey0	LLAMA NANOBODY NB01 (Lama glama)	no annotation	5	MET E 34 ARG E 71 VAL E 78 ALA E 94 TYR E 102	None	0.80A	3qxvE-6ey0E: 18.0	3qxvE-6ey0E: 56.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	5	ALA A 24 MET A 34 ARG A 71 ALA A 94 TYR A 102	None	0.83A	3qxvE-6gzpA: 18.4	3qxvE-6gzpA: undetectable

[["3QXV_E_MTXE2000_1","1guq","Escherichia coli","GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE","PF01087(GalP_UDP_transf);PF02744(GalP_UDP_tr_C)",5,"ARG A 204;ARG A 336;VAL A 213;ALA A 328;TYR A 225","None","1.29A","3qxvE-1guqA:undetectable","3qxvE-1guqA:15.03"],["3QXV_E_MTXE2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  77;VAL A  84;ALA A 103;TYR A 118","None;None;None;None;CGN A   1 ( 4.0A)","0.85A","3qxvE-1i3uA:18.3","3qxvE-1i3uA:59.85"],["3QXV_E_MTXE2000_1","1j33","Thermus thermophilus","COBT","PF02277(DBI_PRT)",5,"ALA A 204;ARG A 200;SER A  64;VAL A 225;ALA A 172","None","1.20A","3qxvE-1j33A:undetectable","3qxvE-1j33A:17.66"],["3QXV_E_MTXE2000_1","1jn0","Spinacia oleracea","GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE A","no annotation",5,"ALA O 257;SER O 294;SER O 295;VAL O 160;ALA O 263","None","1.33A","3qxvE-1jn0O:undetectable","3qxvE-1jn0O:15.22"],["3QXV_E_MTXE2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;ALA B  94;TYR B 102","None","1.07A","3qxvE-1kxtB:16.3","3qxvE-1kxtB:68.75"],["3QXV_E_MTXE2000_1","1pz5","Mus musculus","HEAVY CHAIN OF FAB (SYA\/J6)","PF07654(C1-set);PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;VAL B  78;TYR B 102","None","0.94A","3qxvE-1pz5B:16.4","3qxvE-1pz5B:51.52"],["3QXV_E_MTXE2000_1","1qd0","Lama glama","VHH-R2 ANTI-RR6 ANTIBODY","PF07686(V-set)",5,"MET A  37;ARG A  75;VAL A  82;ALA A 101;TYR A 117","None","1.02A","3qxvE-1qd0A:16.5","3qxvE-1qd0A:71.88"],["3QXV_E_MTXE2000_1","1shm","Lama glama","ANTIBODY RIG","PF07686(V-set)",5,"CYH A  22;ALA A  24;SER A  30;VAL A  78;ALA A  94","None","0.97A","3qxvE-1shmA:18.2","3qxvE-1shmA:65.35"],["3QXV_E_MTXE2000_1","1shm","Lama glama","ANTIBODY RIG","PF07686(V-set)",5,"CYH A  22;SER A  30;MET A  34;VAL A  78;ALA A  94","None","1.01A","3qxvE-1shmA:18.2","3qxvE-1shmA:65.35"],["3QXV_E_MTXE2000_1","1t3q","Pseudomonas putida","QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT","PF01315(Ald_Xan_dh_C);PF02738(Ald_Xan_dh_C2)",5,"ALA B 314;ARG B 416;SER B 354;ARG B 188;ALA B 177","None","1.22A","3qxvE-1t3qB:undetectable","3qxvE-1t3qB:10.68"],["3QXV_E_MTXE2000_1","1t3q","Pseudomonas putida","QUINOLINE 2-OXIDOREDUCTASE LARGE SUBUNIT","PF01315(Ald_Xan_dh_C);PF02738(Ald_Xan_dh_C2)",5,"ALA B 314;ARG B 416;SER B 354;ARG B 188;VAL B 186","None","0.83A","3qxvE-1t3qB:undetectable","3qxvE-1t3qB:10.68"],["3QXV_E_MTXE2000_1","1up2","Mycobacterium tuberculosis","CELA1 PROTEIN","PF01341(Glyco_hydro_6)",5,"ALA A 268;SER A 298;SER A 292;VAL A 226;TYR A 242","None","1.31A","3qxvE-1up2A:undetectable","3qxvE-1up2A:19.86"],["3QXV_E_MTXE2000_1","1urj","Human alphaherpesvirus 1","MAJOR DNA-BINDING PROTEIN","PF00747(Viral_DNA_bp)",5,"ALA A 243;SER A  92;TYR A  95;VAL A  46;ALA A  39","None","1.30A","3qxvE-1urjA:undetectable","3qxvE-1urjA:8.68"],["3QXV_E_MTXE2000_1","2ck0","Mus musculus"," HEAVY CHAIN);PROTEIN (IMMUNOGLOBULIN","PF07654(C1-set);PF07686(V-set)",5,"CYH H  22;ALA H  24;MET H  34;ARG H  71;TYR H 106","None","1.15A","3qxvE-2ck0H:16.7","3qxvE-2ck0H:36.67"],["3QXV_E_MTXE2000_1","2jgv","Staphylococcus aureus","TAGATOSE-6-PHOSPHATE KINASE","PF00294(PfkB)",5,"ALA A 230;ARG A 238;SER A 222;VAL A 181;ALA A 277","None","1.08A","3qxvE-2jgvA:undetectable","3qxvE-2jgvA:16.87"],["3QXV_E_MTXE2000_1","2uxy","Pseudomonas aeruginosa","ALIPHATIC AMIDASE","PF00795(CN_hydrolase)",5,"ALA A 256;ARG A   2;SER A   8;TYR A 255;VAL A  17","None","1.31A","3qxvE-2uxyA:undetectable","3qxvE-2uxyA:16.31"],["3QXV_E_MTXE2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",5,"MET A  34;ARG A  73;VAL A  80;ALA A  99;TYR A 115","None","1.05A","3qxvE-2x6mA:17.4","3qxvE-2x6mA:70.54"],["3QXV_E_MTXE2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",5,"SER A  29;MET A  34;VAL A  78;ALA A  94;TYR A 102","SO4 A1114 (-2.7A);None;None;None;None","0.77A","3qxvE-2xa3A:17.2","3qxvE-2xa3A:69.77"],["3QXV_E_MTXE2000_1","3cp0","Corynebacterium glutamicum","MEMBRANE PROTEIN IMPLICATED IN REGULATION OF MEMBRANE PROTEASE ACTIVITY","PF01957(NfeD)",5,"ALA A  26;SER A  44;TRP A  46;VAL A  32;ALA A  73","None","1.03A","3qxvE-3cp0A:undetectable","3qxvE-3cp0A:23.20"],["3QXV_E_MTXE2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94;TYR B 102","None","0.68A","3qxvE-3g9aB:16.4","3qxvE-3g9aB:64.93"],["3QXV_E_MTXE2000_1","3gkf","Escherichia coli","ALDOLASE LSRF","no annotation",5,"CYH O 239;ALA O 235;SER O 259;VAL O 250;ALA O 268","None","1.15A","3qxvE-3gkfO:undetectable","3qxvE-3gkfO:14.83"],["3QXV_E_MTXE2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 111","None","0.51A","3qxvE-3k7uA:18.7","3qxvE-3k7uA:73.81"],["3QXV_E_MTXE2000_1","3ln9","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10","PF07686(V-set)",5,"ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None;None;None;None;GOL A 137 (-4.8A)","0.84A","3qxvE-3ln9A:16.0","3qxvE-3ln9A:67.94"],["3QXV_E_MTXE2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",5,"ALA A  26;SER A  30;VAL A  81;ALA A 100;TYR A 120","None","0.98A","3qxvE-3qxuA:20.4","3qxvE-3qxuA:96.03"],["3QXV_E_MTXE2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"ALA A  26;SER A  31;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","0.88A","3qxvE-3qxuA:20.4","3qxvE-3qxuA:96.03"],["3QXV_E_MTXE2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"SER A  31;TRP A  34;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","1.44A","3qxvE-3qxuA:20.4","3qxvE-3qxuA:96.03"],["3QXV_E_MTXE2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"CYH A  24;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.69A","3qxvE-3qycA:16.4","3qxvE-3qycA:61.42"],["3QXV_E_MTXE2000_1","3sge","Mus musculus","HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"ALA H  24;SER H  28;MET H  34;ARG H  74;TYR H 104","None","1.02A","3qxvE-3sgeH:16.5","3qxvE-3sgeH:37.20"],["3QXV_E_MTXE2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",5,"ALA A  26;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.66A","3qxvE-3stbA:18.4","3qxvE-3stbA:70.77"],["3QXV_E_MTXE2000_1","3um1","Homo sapiens","BRO1 DOMAIN-CONTAINING PROTEIN BROX","PF03097(BRO1)",5,"CYH A 187;ARG A 145;VAL A 184;ALA A 119;TYR A 122","None","1.15A","3qxvE-3um1A:undetectable","3qxvE-3um1A:15.28"],["3QXV_E_MTXE2000_1","4aq1","Lama glama","NBKB6","PF07686(V-set)",5,"MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","1.03A","3qxvE-4aq1B:18.2","3qxvE-4aq1B:74.19"],["3QXV_E_MTXE2000_1","4bk1","Rhodococcus jostii","PROBABLE SALICYLATE MONOOXYGENASE","PF01494(FAD_binding_3)",5,"ALA A 252;SER A 213;TYR A 253;ALA A 184;TYR A 183","None","1.22A","3qxvE-4bk1A:undetectable","3qxvE-4bk1A:16.79"],["3QXV_E_MTXE2000_1","4bm1","Pleurotus ostreatus","MANGANESE PEROXIDASE 4","PF00141(peroxidase);PF11895(Peroxidase_ext)",5,"ALA A 115;ARG A 126;SER A 286;ARG A 133;ALA A 270","None","1.20A","3qxvE-4bm1A:undetectable","3qxvE-4bm1A:16.27"],["3QXV_E_MTXE2000_1","4czp","Gelatoporia subvermispora","EXTRALONG MANGANESE PEROXIDASE","PF00141(peroxidase);PF11895(Peroxidase_ext)",5,"ALA A 111;ARG A 122;SER A 294;ARG A 129;ALA A 278","None","1.17A","3qxvE-4czpA:undetectable","3qxvE-4czpA:16.67"],["3QXV_E_MTXE2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 116","None","0.76A","3qxvE-4dkaA:18.4","3qxvE-4dkaA:73.23"],["3QXV_E_MTXE2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  97;TYR B 106","None","0.70A","3qxvE-4eigB:16.5","3qxvE-4eigB:66.94"],["3QXV_E_MTXE2000_1","4ej1","Lama glama","NB113 CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"ALA C  97;SER C 101;ARG C  72;VAL C  79;ALA C  50","None","1.16A","3qxvE-4ej1C:17.6","3qxvE-4ej1C:74.22"],["3QXV_E_MTXE2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",5,"MET D  34;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.51A","3qxvE-4fhbD:18.3","3qxvE-4fhbD:71.32"],["3QXV_E_MTXE2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",5,"MET B  36;ARG B  74;VAL B  81;ALA B 100;TYR B 115","None;None;None;None;PCA B   2 ( 3.9A)","0.37A","3qxvE-4gftB:18.6","3qxvE-4gftB:66.93"],["3QXV_E_MTXE2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",6,"ALA E  24;MET E  34;ARG E  72;VAL E  79;ALA E  98;TYR E 112","None","0.68A","3qxvE-4hemE:19.7","3qxvE-4hemE:73.39"],["3QXV_E_MTXE2000_1","4i4n","Vibrio cholerae","INTRACELLULAR PROTEASE\/AMIDASE","no annotation",5,"ALA A 142;SER A  93;TYR A 149;VAL A 173;ALA A  97","None","1.22A","3qxvE-4i4nA:undetectable","3qxvE-4i4nA:17.48"],["3QXV_E_MTXE2000_1","4kf7","Thermothelomyces thermophila","NUP188","PF10487(Nup188)",5,"ALA A1075;ARG A1072;SER A1070;VAL A1029;ALA A1006","None","1.24A","3qxvE-4kf7A:undetectable","3qxvE-4kf7A:8.29"],["3QXV_E_MTXE2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.76A","3qxvE-4krmB:19.7","3qxvE-4krmB:70.16"],["3QXV_E_MTXE2000_1","4krn","Lama glama","NANOBODY\/VHH DOMAIN EGA1","PF07686(V-set)",5,"ARG A  27;MET A  34;VAL A  79;ALA A  98;TYR A 119","None","1.29A","3qxvE-4krnA:17.2","3qxvE-4krnA:70.77"],["3QXV_E_MTXE2000_1","4lf0","Bacillus sp. (in: Bacteria)","ALIPHATIC AMIDASE","PF00795(CN_hydrolase)",5,"ALA A 256;ARG A   2;SER A   8;TYR A 255;VAL A  17","None","1.32A","3qxvE-4lf0A:undetectable","3qxvE-4lf0A:15.22"],["3QXV_E_MTXE2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",6,"CYH B  22;ALA B  24;SER B  28;MET B  34;ARG B  72;VAL B  79","None","0.94A","3qxvE-4lhqB:18.3","3qxvE-4lhqB:63.28"],["3QXV_E_MTXE2000_1","4m3k","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-H7S","PF07686(V-set)",5,"SER B  29;MET B  34;ARG B  71;VAL B  78;ALA B  97","None","1.24A","3qxvE-4m3kB:15.1","3qxvE-4m3kB:68.55"],["3QXV_E_MTXE2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",6,"ALA C  31;MET C  41;ARG C  79;VAL C  86;ALA C 105;TYR C 119","None","0.98A","3qxvE-4nc1C:18.3","3qxvE-4nc1C:70.23"],["3QXV_E_MTXE2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.81A","3qxvE-4nc2B:19.2","3qxvE-4nc2B:70.16"],["3QXV_E_MTXE2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",5,"MET G  34;ARG G  71;VAL G  78;ALA G  97;TYR G 111","None","0.57A","3qxvE-4p2cG:16.0","3qxvE-4p2cG:70.97"],["3QXV_E_MTXE2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",5,"SER G  27;MET G  34;VAL G  78;ALA G  97;TYR G 111","None","1.27A","3qxvE-4p2cG:16.0","3qxvE-4p2cG:70.97"],["3QXV_E_MTXE2000_1","4pdy","Alicyclobacillus acidocaldarius","AMINOGLYCOSIDE PHOSPHOTRANSFERASE","PF01636(APH)",5,"ALA A  86;SER A 112;TRP A 110;VAL A  89;ALA A  56","None;None;HIS A 401 (-3.7A);None;HIS A 401 (-3.5A)","1.22A","3qxvE-4pdyA:undetectable","3qxvE-4pdyA:17.66"],["3QXV_E_MTXE2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None","0.83A","3qxvE-4qlrA:18.6","3qxvE-4qlrA:69.84"],["3QXV_E_MTXE2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",6,"ALA A  25;MET A  35;ARG A  73;VAL A  80;ALA A  99;TYR A 113","None","0.62A","3qxvE-4qo1A:18.1","3qxvE-4qo1A:62.70"],["3QXV_E_MTXE2000_1","4qpk","Brucella abortus","PHOSPHOTRANSFERASE","PF10090(HPTransfase)",5,"ALA A  65;ARG A  19;SER A  26;ALA A  60;TYR A  91","GOL A 301 (-3.6A);GOL A 302 (-3.0A);None;None;GOL A 301 (-4.9A)","1.30A","3qxvE-4qpkA:undetectable","3qxvE-4qpkA:20.00"],["3QXV_E_MTXE2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",6,"CYH a  23;ALA a  25;ARG a  73;VAL a  80;ALA a  99;TYR a 117","None","0.82A","3qxvE-4tvsa:18.7","3qxvE-4tvsa:72.87"],["3QXV_E_MTXE2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",5,"ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","0.99A","3qxvE-4w6yB:17.6","3qxvE-4w6yB:69.47"],["3QXV_E_MTXE2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",5,"MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 118","None","1.31A","3qxvE-4w6yB:17.6","3qxvE-4w6yB:69.47"],["3QXV_E_MTXE2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",5,"ALA D 824;MET D 834;ARG D 872;ALA D 898;TYR D 910","None","0.66A","3qxvE-4weuD:18.5","3qxvE-4weuD:72.00"],["3QXV_E_MTXE2000_1","4wj1","Mycolicibacterium smegmatis","ANTIGEN MTB48, MYCOBACTERIAL PROTEIN","no annotation",5,"ALA A 220;SER A  41;TYR A 266;VAL A 225;ALA A 150","None","1.16A","3qxvE-4wj1A:undetectable","3qxvE-4wj1A:17.65"],["3QXV_E_MTXE2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",5,"ALA C  24;MET C  34;VAL C  78;ALA C  97;TYR C 107","None","0.87A","3qxvE-4xt1C:16.2","3qxvE-4xt1C:68.75"],["3QXV_E_MTXE2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",5,"ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.78A","3qxvE-5a2kH:16.4","3qxvE-5a2kH:29.03"],["3QXV_E_MTXE2000_1","5czr","Homo sapiens","CADHERIN-RELATED FAMILY MEMBER 2","PF00028(Cadherin)",5,"ALA A  62;MET A  42;VAL A  52;ALA A  47;TYR A  48","None","1.28A","3qxvE-5czrA:undetectable","3qxvE-5czrA:18.98"],["3QXV_E_MTXE2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",5,"ALA A  24;MET A  34;ARG A  71;VAL A  78;TYR A 102","None","0.86A","3qxvE-5fwoA:18.2","3qxvE-5fwoA:68.18"],["3QXV_E_MTXE2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",5,"MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.58A","3qxvE-5fwoA:18.2","3qxvE-5fwoA:68.18"],["3QXV_E_MTXE2000_1","5gru","Mus musculus","DIABODY PROTEIN","PF07686(V-set)",5,"ALA L 153;SER L 214;SER L 215;MET L 125;ALA L 146","ALA L 153 ( 0.0A);SER L 214 ( 0.0A);SER L 215 ( 0.0A);MET L 125 ( 0.0A);ALA L 146 ( 0.0A)","1.25A","3qxvE-5gruL:16.2","3qxvE-5gruL:44.80"],["3QXV_E_MTXE2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"CYH B  22;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","0.81A","3qxvE-5gxbB:17.4","3qxvE-5gxbB:68.42"],["3QXV_E_MTXE2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",5,"ALA B  24;MET B  34;VAL B  77;ALA B  96;TYR B 108","None","1.00A","3qxvE-5hvfB:15.1","3qxvE-5hvfB:69.35"],["3QXV_E_MTXE2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",5,"ALA B  23;MET B  33;ARG B  71;ALA B  97;TYR B 113","None","0.82A","3qxvE-5imlB:19.9","3qxvE-5imlB:75.40"],["3QXV_E_MTXE2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",5,"MET B  33;ARG B  71;VAL B  78;ALA B  97;TYR B 113","None","0.43A","3qxvE-5imlB:19.9","3qxvE-5imlB:75.40"],["3QXV_E_MTXE2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",6,"ALA C  25;MET C  35;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.89A","3qxvE-5j1sC:15.9","3qxvE-5j1sC:66.17"],["3QXV_E_MTXE2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",5,"CYH C  23;ALA C  25;VAL C  79;ALA C  98;TYR C 112","None","0.68A","3qxvE-5j1sC:15.9","3qxvE-5j1sC:66.17"],["3QXV_E_MTXE2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",5,"CYH C  23;SER C  31;VAL C  79;ALA C  98;TYR C 112","None","1.27A","3qxvE-5j1sC:15.9","3qxvE-5j1sC:66.17"],["3QXV_E_MTXE2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",6,"CYH B  22;ALA B  24;ARG B  76;VAL B  83;ALA B 102;TYR B 117","None","0.68A","3qxvE-5j56B:17.5","3qxvE-5j56B:67.18"],["3QXV_E_MTXE2000_1","5jds","Camelidae","NANOBODY","PF07686(V-set)",5,"SER B  29;MET B  34;VAL B  79;ALA B  98;TYR B 117","None","1.08A","3qxvE-5jdsB:16.7","3qxvE-5jdsB:67.41"],["3QXV_E_MTXE2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",5,"MET D  34;ARG D  71;VAL D  78;ALA D  97;TYR D 108","None","0.94A","3qxvE-5jqhD:16.1","3qxvE-5jqhD:70.16"],["3QXV_E_MTXE2000_1","5kel","Homo sapiens","C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN","PF07686(V-set)",5,"ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.85A","3qxvE-5kelH:14.8","3qxvE-5kelH:51.15"],["3QXV_E_MTXE2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",5,"ALA B  24;ARG B  72;VAL B  79;ALA B  98;TYR B 122","None","0.51A","3qxvE-5lhqB:18.1","3qxvE-5lhqB:64.66"],["3QXV_E_MTXE2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.95A","3qxvE-5lmjA:16.7","3qxvE-5lmjA:73.23"],["3QXV_E_MTXE2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",5,"ALA C  27;MET C  37;ARG C  75;ALA C 101;TYR C 117","None;None;None;None;ACT C 202 (-4.4A)","0.58A","3qxvE-5lwfC:18.5","3qxvE-5lwfC:68.80"],["3QXV_E_MTXE2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",5,"MET C  37;ARG C  75;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;ACT C 202 (-4.4A)","0.54A","3qxvE-5lwfC:18.5","3qxvE-5lwfC:68.80"],["3QXV_E_MTXE2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",5,"MET L  34;ARG L  72;VAL L  79;ALA L  98;TYR L 114","None","0.55A","3qxvE-5o8fL:18.1","3qxvE-5o8fL:68.46"],["3QXV_E_MTXE2000_1","5tws","Homo sapiens","HUMAN DNA POLYMERASE MU","PF10391(DNA_pol_lambd_f);PF14716(HHH_8);PF14791(DNA_pol_B_thumb);PF14792(DNA_pol_B_palm)",5,"ALA A 159;SER A 209;SER A 210;VAL A 228;ALA A 164","None","1.31A","3qxvE-5twsA:undetectable","3qxvE-5twsA:15.87"],["3QXV_E_MTXE2000_1","5u3j","Homo sapiens","DH511.1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"CYH H  22;ALA H  24;MET H  34;ARG H  71;ALA H  94","None","0.94A","3qxvE-5u3jH:16.0","3qxvE-5u3jH:54.07"],["3QXV_E_MTXE2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"MET p  34;ARG p  72;VAL p  79;ALA p  98;TYR p 114","None","0.70A","3qxvE-5uk4p:17.7","3qxvE-5uk4p:71.43"],["3QXV_E_MTXE2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"ALA d  24;ARG d  72;VAL d  79;ALA d  98;TYR d 113","None","0.75A","3qxvE-5ukbd:19.3","3qxvE-5ukbd:70.97"],["3QXV_E_MTXE2000_1","5vaq","Lama glama","NB914","no annotation",5,"ALA B  24;SER B  30;ARG B  72;VAL B  79;ALA B  98","None","1.05A","3qxvE-5vaqB:19.3","3qxvE-5vaqB:75.00"],["3QXV_E_MTXE2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",5,"MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.61A","3qxvE-5vxjB:15.7","3qxvE-5vxjB:63.08"],["3QXV_E_MTXE2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",6,"CYH B  22;ALA B  24;MET B  34;ARG B  73;ALA B  99;TYR B 106","None","0.80A","3qxvE-5vxlB:16.6","3qxvE-5vxlB:66.41"],["3QXV_E_MTXE2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",6,"CYH B  22;MET B  34;ARG B  73;VAL B  80;ALA B  99;TYR B 106","None","0.66A","3qxvE-5vxlB:16.6","3qxvE-5vxlB:66.41"],["3QXV_E_MTXE2000_1","5wa3","Thermobispora bispora","PYRIDINE SYNTHASE TBTD","no annotation",5,"ALA A 343;SER A 229;TYR A 347;VAL A 183;ALA A 173","None","1.20A","3qxvE-5wa3A:undetectable","3qxvE-5wa3A:19.49"],["3QXV_E_MTXE2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",5,"ALA A1024;MET A1034;VAL A1078;ALA A1097;TYR A1107","None","0.97A","3qxvE-5wb1A:15.0","3qxvE-5wb1A:15.08"],["3QXV_E_MTXE2000_1","5wb2","synthetic construct","NANOBODY B1","no annotation",5,"ALA D  24;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.97A","3qxvE-5wb2D:15.8","3qxvE-5wb2D:68.29"],["3QXV_E_MTXE2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",5,"ALA A  43;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.79A","3qxvE-5x0tA:16.4","3qxvE-5x0tA:31.40"],["3QXV_E_MTXE2000_1","6b3r","Mus musculus","PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1","no annotation",5,"ALA A1174;ARG A1176;SER A1250;VAL A1742;TYR A1184","None","1.30A","3qxvE-6b3rA:undetectable","3qxvE-6b3rA:21.54"],["3QXV_E_MTXE2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",5,"ALA A  24;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.78A","3qxvE-6dbeA:17.1","3qxvE-6dbeA:undetectable"],["3QXV_E_MTXE2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 107","None","1.18A","3qxvE-6dbeA:17.1","3qxvE-6dbeA:undetectable"],["3QXV_E_MTXE2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"MET C  34;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.59A","3qxvE-6ehgC:18.8","3qxvE-6ehgC:57.14"],["3QXV_E_MTXE2000_1","6ey0","Lama glama","LLAMA NANOBODY NB01","no annotation",5,"MET E  34;ARG E  71;VAL E  78;ALA E  94;TYR E 102","None","0.80A","3qxvE-6ey0E:18.0","3qxvE-6ey0E:56.60"],["3QXV_E_MTXE2000_1","6gzp","Lama glama","NANOBODY","no annotation",5,"ALA A  24;MET A  34;ARG A  71;ALA A  94;TYR A 102","None","0.83A","3qxvE-6gzpA:18.4","3qxvE-6gzpA:undetectable"]]